These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 26538622)

  • 1. Targeted Therapy Makes Inroads in Medulloblastoma.
    Schmidt C
    J Natl Cancer Inst; 2015 Nov; 107(11):djv353. PubMed ID: 26538622
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
    Rudin CM; Hann CL; Laterra J; Yauch RL; Callahan CA; Fu L; Holcomb T; Stinson J; Gould SE; Coleman B; LoRusso PM; Von Hoff DD; de Sauvage FJ; Low JA
    N Engl J Med; 2009 Sep; 361(12):1173-8. PubMed ID: 19726761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists.
    Metcalfe C; de Sauvage FJ
    Cancer Res; 2011 Aug; 71(15):5057-61. PubMed ID: 21771911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of hedgehog signaling pathway inhibitors.
    Liu H; Gu D; Xie J
    Chin J Cancer; 2011 Jan; 30(1):13-26. PubMed ID: 21192841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHH inhibitors for the treatment of medulloblastoma.
    Samkari A; White J; Packer R
    Expert Rev Neurother; 2015; 15(7):763-70. PubMed ID: 26027634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition.
    Metcalfe C; Alicke B; Crow A; Lamoureux M; Dijkgraaf GJ; Peale F; Gould SE; de Sauvage FJ
    Cancer Res; 2013 Dec; 73(23):7034-42. PubMed ID: 24154871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with Hedgehog pathway inhibitors.
    Low JA; de Sauvage FJ
    J Clin Oncol; 2010 Dec; 28(36):5321-6. PubMed ID: 21041712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mTOR as a Therapeutic Approach in Medulloblastoma.
    Aldaregia J; Odriozola A; Matheu A; Garcia I
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood Brain Barrier Phenotype Is Determined by Medulloblastoma Subtype.
    Cancer Discov; 2016 Jun; 6(6):OF16. PubMed ID: 27080336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The rationale for targeted therapies in medulloblastoma.
    MacDonald TJ; Aguilera D; Castellino RC
    Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medulloblastoma growth inhibition by hedgehog pathway blockade.
    Berman DM; Karhadkar SS; Hallahan AR; Pritchard JI; Eberhart CG; Watkins DN; Chen JK; Cooper MK; Taipale J; Olson JM; Beachy PA
    Science; 2002 Aug; 297(5586):1559-61. PubMed ID: 12202832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
    Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
    Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sonic Hedgehog signaling pathway: from embryology to molecular targeted therapies].
    Watson S; Serrate C; Vignot S
    Bull Cancer; 2010 Dec; 97(12):1477-83. PubMed ID: 21220225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma.
    Asklund T; Henriksson R; Axelsson J; Bergström Å; Kasper M; Ögren M; Toftgård R; Riklund KÅ
    Acta Oncol; 2013 May; 52(4):862-6. PubMed ID: 23013267
    [No Abstract]   [Full Text] [Related]  

  • 17. GDC-0449-a potent inhibitor of the hedgehog pathway.
    Robarge KD; Brunton SA; Castanedo GM; Cui Y; Dina MS; Goldsmith R; Gould SE; Guichert O; Gunzner JL; Halladay J; Jia W; Khojasteh C; Koehler MF; Kotkow K; La H; Lalonde RL; Lau K; Lee L; Marshall D; Marsters JC; Murray LJ; Qian C; Rubin LL; Salphati L; Stanley MS; Stibbard JH; Sutherlin DP; Ubhayaker S; Wang S; Wong S; Xie M
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5576-81. PubMed ID: 19716296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent Antineoplastic Effects of Combined PI3Kα-MNK Inhibition in Medulloblastoma.
    Eckerdt F; Bell JB; Beauchamp EM; Clymer J; Blyth GT; Kosciuczuk EM; Ma Q; Chen DZ; Horbinski C; Goldman S; Munshi HG; Hashizume R; Platanias LC
    Mol Cancer Res; 2019 Jun; 17(6):1305-1315. PubMed ID: 30842251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of estrogen receptor signaling to improve outlook for medulloblastoma sufferers.
    Belcher SM
    Future Oncol; 2009 Aug; 5(6):751-4. PubMed ID: 19663723
    [No Abstract]   [Full Text] [Related]  

  • 20. The cellular and developmental biology of medulloblastoma: current perspectives on experimental therapeutics.
    Srivastava VK; Nalbantoglu J
    Cancer Biol Ther; 2010 Jun; 9(11):843-52. PubMed ID: 20372085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.